In 2016, concerns regarding retinopathy associated with GLP-1 were first raised in the Semaglutide Unabated Sustainability in Treatment of T2DM (SUSTAIN) 6 trial with semaglutide [89]
The idea of compounded Semaglutide with B12 isn't just about enhancing weight loss but also about improving overall health
Clinical trials leading to FDA approval demonstrated significant visceral fat reduction in patients with excess abdominal fat accumulation, validating what clinicians now see consistently in practice
This marked a key moment in the companys diabetes strategy, supported by strong clinical results showing better blood sugar control and weight loss
According to the FDA prescribing information for both Ozempic and Wegovy, nausea, vomiting, diarrhea, abdominal pain, and constipation occur in a significant proportion of patients, particularly during dose escalation
Calanna, M